Survival Outcomes of Ovarian Malignancies in Chinese Population
- Conditions
- SurvivalOvarian Neoplasms
- Registration Number
- NCT03291262
- Lead Sponsor
- Lei Li
- Brief Summary
This study aims to determine survival outcomes (overall survival and progression-free survival) of primary ovarian malignancies in China and relevant risk factors in a prospective cohort study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 5000
Inclusion Criteria
- Primary ovarian malignancies.
Exclusion Criteria
- Metastatic malignancies to ovaries.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival 5 years Periods from diagnosis of ovarian cancer to death
Progression-free survival 5 years Periods from diagnosis of ovarian cancer or remission of disease to next recurrence
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence survival outcomes in Chinese ovarian malignancy patients as studied in NCT03291262?
How does the survival rate of ovarian malignancies in China compare to global standard-of-care treatment outcomes?
Are there specific biomarkers identified in NCT03291262 that correlate with progression-free survival in ovarian cancer subtypes?
What adverse events are associated with primary ovarian malignancies in the Chinese population according to NCT03291262?
What combination therapies or targeted agents show promise for improving survival in Chinese ovarian cancer patients beyond NCT03291262 findings?
Trial Locations
- Locations (1)
Lei Li
🇨🇳Beijing, China/Beiing, China
Lei Li🇨🇳Beijing, China/Beiing, ChinaLei L Li, MDContact13911988831lileigh@163.com